Medication use during pregnancy in Omani women
- 318 Downloads
Objective The aim of this study was to evaluate medication use pattern in a university tertiary hospital in the Sultanate of Oman. Setting The study was conducted at the Sultan Qaboos University Hospital (SQUH) and the SQUH Family and Community Medicine clinic (FAMCO), Muscat, Sultanate of Oman during 7th to 25th June 2008. Method The medication use pattern was evaluated in women attending FAMCO and the standard antenatal clinics at the hospital. Women were interviewed in different gestational ages using a structured questionnaire. The Electronic Patient Record (EPR) was reviewed to acquire additional information on medication use. Medications were classified according to the US FDA risk classification. Main outcome measure Medication used including prescribed medications, OTC medications, or herbal treatment during the current pregnancy and 3 months prior to conception. Results The study included a total of 139 pregnant mothers with an overall mean age of 28 ± 5 years ranging from 19 to 45 years. There was a slight overall reduction in the medication use including prescribed medications. However, there was a significant increase in utilization of vitamins and supplements (84–95% vs. 12% in the 3-months prior, P < 0.001) as well as herbal preparations (16–19% vs. 7% in the 3-months prior, P = 0.011) throughout pregnancy (P < 0.010). The use of category A medications increased in all trimester (43–52% vs. 13% in the 3 months prior, P < 0.010) while a reduction in the use of category C (for first and third trimester, P < 0.050) and D medications was seen. A reduction in the use of teratogenic drugs in all trimesters (P < 0.010) was also observed. Conclusion The prescribing of vitamins and minerals was optimal. However, the common use of herbal supplements observed warrants special attention due to their unknown risks. The conclusions should be interpreted in light of the study’s limitations
KeywordsFDA pregnancy risk category Medication Oman Pregnancy
We would like to thank the women who participated in the study, to the Pharmacy and the Obstetric/Gynecology departments who provided their support to this study.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors
Conflicts of interest
- 4.Australian Drug Evaluation Committee. Prescribing medicines in pregnancy. 4th ed. Woden, Australia: Aust Gov Pub Unit; 1999.Google Scholar
- 5.Food and Drug Administration. Requirements on content and format of labeling for human prescription drug and biological products. Fed Regist. 2006;71:3921–97.Google Scholar
- 11.Rohra DK, Das N, Azam SI, Solangi NA, Memon Z, Shaikh AM, Khan NH. Drug prescribing patterns during pregnancy in the tertiary care hospitals of Pakistan: a cross sectional study. BMC Pregnancy Childbirth. 2008;8:24.Google Scholar
- 13.Al-Humayyd MS, Babay ZH. Pattern of drug prescribing during pregnancy in Saudi women: a retrospective study. Saudi Pharm J. 2006;14(3,4):201–7.Google Scholar
- 14.Lexi-Drugs Online [database on the Internet]. Hudson, OH: Lexi-Comp, Inc.; 2008 [cited 30 July 2008]. Available from: http://online.lexi.com. Subscription required to view.
- 15.Briggs GG, Freeman RK, Summer JY. Drugs in pregnancy and lactation. 6th ed. Baltimore: Williams and Wilkins; 2002.Google Scholar
- 16.StataCorp. Stata: Release 11.1. Statistical Software. College Station, TX: StataCorp LP; 2010.Google Scholar
- 25.Byrne MJ, Semple SJ, Coulthard KP. Complementary medicine use during pregnancy. Interviews with 48 women in a hospital antenatal ward. Aust Pharmacist. 2002;21:954–9.Google Scholar